SingleMetabolic / GLP-1

SLU-PP-332 5mg

Preclinical synthetic pan-ERR agonist studied as an exercise mimetic for mitochondrial oxidation and metabolic regulation.

Mechanism

Acts as a synthetic pan-agonist across estrogen-related receptors (ERRα, ERRβ, and ERRγ) to induce an aerobic-exercise gene program and upregulate mitochondrial respiration.

Dosing

Preclinical murine protocols document an initial regimen of 625 mcg administered twice daily (1,250 mcg per day total).

Reconstitution

Diluting a 5 mg vial with 3.0 mL of bacteriostatic water creates an approximate concentration of 1.67 mg/mL.

Storage

Store unmixed lyophilized vials frozen at -20 °C, and keep the reconstituted solution refrigerated between 2 °C and 8 °C protected from light without refreezing.

Mix & measure SLU-PP-332 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure SLU-PP-332 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.67mg/mL

Draw volume0.375mL

On the syringe37.5units

Total doses in vial: 8.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	625 mcg (2× daily · 1,250 mcg/day)	37.5 units (0.375 mL) per dose
Weeks 3–8	1,250 mcg (2× daily · 2,500 mcg/day)	75 units (0.75 mL) per dose

Reconstitution Steps

1
Aspirate exactly 3.0 mL of bacteriostatic water using a sterile syringe.
2
Introduce the diluent slowly against the inside glass wall of the vial to minimize agitation.
3
Swirl the vial gently until the cake has fully dissolved without shaking.
4
Affix a label noting concentration and date, then transfer immediately to refrigerated storage at 2–8 °C away from light.

Supplies Needed

Peptide Vial

SLU-PP-332 lyophilized powder (5 mg vial)

Insulin Syringes (U-100)

1 mL syringes used to accurately draw and administer unit-level doses

Bacteriostatic Water

3.0 mL of sterile bacteriostatic diluent required per 5 mg vial

Alcohol Swabs

Antiseptic wipes used to sterilize the vial stopper and injection interface

Why researchers study it

Fat loss and weight management mechanisms

Running endurance and physical capacity enhancement

Mitochondrial biogenesis and lipid oxidation pathways

Myocardial support and cardiac failure models

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

SLU-PP-332 is an investigational small-molecule agonist developed to target estrogen-related receptors, functioning as an experimental metabolic modulator. Synthesized to evaluate the signaling pathways underlying physical endurance, it engages cellular machinery comparable to sustained aerobic physical exertion. Preclinical research primarily focuses on how this agent alters energetic balance, stimulates fatty acid combustion, and drives transcriptional changes within skeletal muscle and myocardial tissues. Because all existing scientific findings originate exclusively from rodent models, translational parameters in human systems remain entirely unestablished.

References

1.ACS Chemical Biology, 2023 — Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic-exercise response and enhances exercise capacity
2.J. Pharmacology and Experimental Therapeutics, 2024 — A synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome in mice
3.Circulation, 2024 — Novel pan-ERR agonists ameliorate heart failure through enhanced cardiac fatty-acid metabolism and mitochondrial function
4.American Journal of Pathology, 2023 — Estrogen-related receptor agonism reverses mitochondrial dysfunction and inflammation in the aging kidney